April 20, 2016
A Delaware federal judge on Wednesday upheld the validity of five patents licensed by Pfizer Inc. protecting its Toviaz overactive-bladder treatment, dealing a blow to Sandoz Inc. and other drug companies accused of infringement in Pfizer's consolidated suit.
August 12, 2015
Several drug companies including Sandoz Inc. want a Delaware federal judge to amend his judgment directed after a trial that a Pfizer Inc. patent related to the overactive-bladder medication Toviaz is not invalid as indefinite.
July 23, 2015
A Delaware federal judge ruled Wednesday that a Pfizer Inc. patent related to the overactive-bladder medication Toviaz, which the company asserted against Sandoz Inc. and others, is not invalid as indefinite.
July 21, 2015
A Delaware federal judge ruled Tuesday that Sandoz Inc. infringed two of five patents licensed by Pfizer Inc. protecting the latter's Toviaz overactive bladder treatment, saying the testimony of Pfizer's expert witness was credible and persuasive.
June 24, 2013
Pfizer Inc. hit Alkem Laboratories Ltd. and Sandoz Inc. with lawsuits Friday aimed at blocking their recent bids to launch generic versions of Pfizer's Toviaz, a drug used to treat overactive bladders.